Status:

COMPLETED

Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine

Lead Sponsor:

Pfizer

Conditions:

Migraine

Acute Treatment of Migraine

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

The primary purpose of this study is to evaluate the efficacy of rimegepant (BMS-927711) compared with placebo in the acute treatment of migraine as measured by Pain Freedom (headache pain intensity l...

Detailed Description

Intervention Model: Parallel Versus Comparator + Placebo

Eligibility Criteria

Inclusion

  • Key
  • Patient with at least 1-year history of migraines (with or without aura) including the following:
  • Migraine attacks more than 1 year with age of onset prior to 50 years of age
  • Migraine attacks, on average, last about 4 - 72 hours if untreated
  • No more than 8 attacks of moderate to severe intensity per month within last 3 months
  • Patient must be able to distinguish migraine attacks from tension/cluster attacks and must have consistent migraine headaches of at least 2 migraine headaches attacks of moderate to severe intensity in each of the last 3 months
  • Less than 15 days of headache (migraine or non-migraine) per month in each of 3 months prior to screening
  • Male and female ≥ 18 years and ≤ age 65
  • No clinically significant abnormality identified on the medical or laboratory evaluation
  • Key

Exclusion

  • Patient has a history of basilar migraine or hemiplegic migraine
  • Patient does not receive migraine relief from triptan migraine treatment
  • Medications that may alter the pH of the stomach (acid reducing agents), such as H-2 antagonists, Proton Pump inhibitors (PPI), antacids
  • History of ergotamine or triptan intake greater than/equal 10 days per month on a regular basis for greater than 3 months
  • History of non-narcotic analgesic intake on greater then/equal 15 days per month for greater than/equal 3 months

Key Trial Info

Start Date :

October 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2012

Estimated Enrollment :

1026 Patients enrolled

Trial Details

Trial ID

NCT01430442

Start Date

October 1 2011

End Date

May 1 2012

Last Update

February 28 2023

Active Locations (41)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 11 (41 locations)

1

Mayo Clinic Arizona

Scottsdale, Arizona, United States, 85259

2

Clinical Res. Advantage Inc/ Desert Clinical Research Llc

Tempe, Arizona, United States, 85282

3

University Of California, San Francisco

San Francisco, California, United States, 94115

4

California Medical Clinic For Headache

Santa Monica, California, United States, 90404

Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine | DecenTrialz